AU744824B2 - Improved process for obtaining insulin precursors having correctly bonded cystine bridges - Google Patents

Improved process for obtaining insulin precursors having correctly bonded cystine bridges Download PDF

Info

Publication number
AU744824B2
AU744824B2 AU80763/98A AU8076398A AU744824B2 AU 744824 B2 AU744824 B2 AU 744824B2 AU 80763/98 A AU80763/98 A AU 80763/98A AU 8076398 A AU8076398 A AU 8076398A AU 744824 B2 AU744824 B2 AU 744824B2
Authority
AU
Australia
Prior art keywords
cysteine
amino acid
approximately
insulin
precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU80763/98A
Other languages
English (en)
Other versions
AU8076398A (en
Inventor
Reinhold Keller
Franz-Josef Rubroder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of AU8076398A publication Critical patent/AU8076398A/en
Assigned to AVENTIS PHARMA DEUTSCHLAND GMBH reassignment AVENTIS PHARMA DEUTSCHLAND GMBH Amend patent request/document other than specification (104) Assignors: HOECHST MARION ROUSSEL DEUTSCHLAND GMBH
Assigned to AVENTIS PHARMA DEUTSCHLAND GMBH reassignment AVENTIS PHARMA DEUTSCHLAND GMBH Amend patent request/document other than specification (104) Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Application granted granted Critical
Publication of AU744824B2 publication Critical patent/AU744824B2/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request to Amend Deed and Register Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU80763/98A 1997-08-18 1998-08-17 Improved process for obtaining insulin precursors having correctly bonded cystine bridges Expired AU744824B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19735711A DE19735711C2 (de) 1997-08-18 1997-08-18 Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
DE19735711.3 1997-08-18

Publications (2)

Publication Number Publication Date
AU8076398A AU8076398A (en) 1999-02-25
AU744824B2 true AU744824B2 (en) 2002-03-07

Family

ID=7839275

Family Applications (1)

Application Number Title Priority Date Filing Date
AU80763/98A Expired AU744824B2 (en) 1997-08-18 1998-08-17 Improved process for obtaining insulin precursors having correctly bonded cystine bridges

Country Status (20)

Country Link
US (3) US5986048A (enExample)
EP (2) EP0980874B1 (enExample)
JP (1) JP4291900B2 (enExample)
KR (2) KR100537842B1 (enExample)
CN (3) CN101186940B (enExample)
AR (1) AR016821A1 (enExample)
AT (2) ATE217636T1 (enExample)
AU (1) AU744824B2 (enExample)
BR (2) BR9803755A (enExample)
CA (1) CA2245151C (enExample)
CZ (1) CZ295679B6 (enExample)
DE (3) DE19735711C2 (enExample)
DK (2) DK0980874T3 (enExample)
ES (2) ES2176870T3 (enExample)
HU (2) HU228161B1 (enExample)
ID (1) ID20717A (enExample)
PL (1) PL191901B1 (enExample)
PT (2) PT980874E (enExample)
RU (2) RU2205836C2 (enExample)
TR (1) TR199801587A3 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
DE19930676B4 (de) 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
JP2003530316A (ja) 1999-12-22 2003-10-14 ノボ ノルディスク アクティーゼルスカブ スクランブルした一本鎖ポリペプチドの抽出的再生法
AU2001280436A1 (en) * 2000-07-12 2002-01-21 Eli Lilly And Company Process to increase protein stability
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
DE102004015965A1 (de) * 2004-04-01 2005-10-20 Aventis Pharma Gmbh Verfahren zur Gewinnung von Insulinen durch verbesserte Luftbegasung der Faltung
JP5036727B2 (ja) 2005-12-22 2012-09-26 ジェネンテック， インコーポレイテッド ヘパリン結合タンパク質の組み換え体産生
CN101506222B (zh) * 2006-07-14 2013-10-02 健泰科生物技术公司 重组蛋白的重折叠
CA2692585A1 (en) * 2007-07-03 2010-01-04 Amgen Inc. Measurement of protein using inclusion body dry weight
RU2451750C2 (ru) * 2007-09-24 2012-05-27 Общество С Ограниченной Ответственностью "Герофарм" Способ получения рекомбинантного с-пептида проинсулина человека
BRPI0907371A2 (pt) 2008-01-09 2015-11-24 Sanofi Aventis Deutschland derivados de insulina com um perfil de tempo-ação muito retardado
US9296806B2 (en) * 2008-04-30 2016-03-29 Wockhardt Limited Processes for refolding of insulin
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
CA2780043C (en) 2009-11-13 2019-01-29 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist and methionine
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
SG187904A1 (en) 2010-08-30 2013-04-30 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US12157766B2 (en) * 2012-08-05 2024-12-03 Absci Corporation Cytoplasmic expression system
US10421795B2 (en) 2012-12-17 2019-09-24 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
WO2014133324A1 (ko) * 2013-02-26 2014-09-04 한미약품 주식회사 신규한 인슐린 아날로그 및 이의 용도
CN103694339B (zh) * 2013-12-04 2017-10-13 珠海联邦制药股份有限公司 一种甘精胰岛素前体的复性方法
US10407483B2 (en) 2014-03-14 2019-09-10 Merck Sharp & Dohme Corp. Purifying insulin using cation exchange and reverse phase chromatography in the presence of an organic modifier and elevated temperature
SI3229828T1 (sl) 2014-12-12 2023-06-30 Sanofi-Aventis Deutschland Gmbh Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN104911203A (zh) * 2015-06-30 2015-09-16 成都易胜科生物科技有限公司 一种重组人胰岛素的工业制备方法
EP3344651B1 (en) 2015-09-02 2022-03-02 Merck Sharp & Dohme Corp. A process for obtaining insulin with correctly formed disulfide bonds
US10689430B2 (en) 2016-05-25 2020-06-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
WO2018018613A1 (zh) 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN113773400B (zh) * 2020-06-09 2023-08-18 宁波鲲鹏生物科技有限公司 一种门冬胰岛素衍生物及其应用
CN113773391B (zh) * 2020-06-09 2023-10-20 宁波鲲鹏生物科技有限公司 一种门冬胰岛素的制备方法
CN113773396A (zh) * 2020-06-10 2021-12-10 宁波鲲鹏生物科技有限公司 一种地特胰岛素衍生物及其应用
JP7749397B2 (ja) * 2021-09-30 2025-10-06 キヤノン株式会社 超音波ファントム及び超音波ファントムの製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) * 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DE3501641A1 (de) * 1985-01-19 1986-07-24 Hoechst Ag, 6230 Frankfurt Verfahren zur gewinnung von insulin-vorlaeufern aus reaktionsgemischen, die bei der faltung von insulin-vorlaeufern aus den entsprechenden s-sulfonaten anfallen
GR1005153B (el) * 1989-08-29 2006-03-13 The General Hospital Corporation Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
RU2045535C1 (ru) * 1991-06-18 1995-10-10 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН Способ получения проинсулина человека
ES2097426T3 (es) * 1992-12-02 1997-04-01 Hoechst Ag Procedimiento para la obtencion de proinsulina con puentes de cistina correctamente unidos.
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
RU2081122C1 (ru) * 1994-06-16 1997-06-10 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН Способ выделения и очистки инсулина или его биотехнологических предшественников
PT871474E (pt) * 1994-12-29 2007-02-28 Ferring Int Ct Sa Produção de insulina humana
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken

Also Published As

Publication number Publication date
EP0980874B1 (de) 2002-05-02
TR199801587A2 (xx) 1999-03-22
HU228161B1 (en) 2013-01-28
CN1209437A (zh) 1999-03-03
HU9801886D0 (en) 1998-10-28
DK0980874T3 (da) 2002-08-19
HUP9801886A3 (en) 1999-06-28
CA2245151C (en) 2009-10-06
EP0906918B1 (de) 2002-05-15
JPH11130798A (ja) 1999-05-18
ATE217012T1 (de) 2002-05-15
ES2177178T3 (es) 2002-12-01
CN1483831B (zh) 2012-06-13
HK1119449A1 (en) 2009-03-06
DE19735711A1 (de) 1999-02-25
HK1061870A1 (en) 2004-10-08
CN1483831A (zh) 2004-03-24
DE59804121D1 (de) 2002-06-20
ATE217636T1 (de) 2002-06-15
KR100574580B1 (ko) 2006-04-28
PL328108A1 (en) 1999-03-01
JP4291900B2 (ja) 2009-07-08
PT906918E (pt) 2002-10-31
US6727346B2 (en) 2004-04-27
CZ259898A3 (cs) 1999-03-17
HK1018464A1 (en) 1999-12-24
CN101186940A (zh) 2008-05-28
KR100537842B1 (ko) 2006-03-23
BRPI9816233B8 (pt) 2021-05-25
HUP9801886A2 (hu) 1999-01-28
CA2245151A1 (en) 1999-02-18
HU228203B1 (en) 2013-01-28
CN1132845C (zh) 2003-12-31
DE19735711C2 (de) 2001-04-26
RU2205836C2 (ru) 2003-06-10
TR199801587A3 (tr) 1999-03-22
HU0600287D0 (en) 2006-05-29
US20020156234A1 (en) 2002-10-24
CZ295679B6 (cs) 2005-09-14
KR19990023651A (ko) 1999-03-25
AU8076398A (en) 1999-02-25
US6380355B1 (en) 2002-04-30
EP0906918A2 (de) 1999-04-07
BR9803755A (pt) 2000-03-28
ES2176870T3 (es) 2002-12-01
KR20050067371A (ko) 2005-07-01
PT980874E (pt) 2002-10-31
RU2302882C2 (ru) 2007-07-20
US5986048A (en) 1999-11-16
EP0980874A1 (de) 2000-02-23
ID20717A (id) 1999-02-18
CN101186940B (zh) 2012-02-08
DE59803985D1 (de) 2002-06-06
BRPI9816233B1 (pt) 2016-09-27
DK0906918T3 (da) 2002-09-09
AR016821A1 (es) 2001-08-01
EP0906918A3 (de) 1999-08-11
PL191901B1 (pl) 2006-07-31

Similar Documents

Publication Publication Date Title
AU744824B2 (en) Improved process for obtaining insulin precursors having correctly bonded cystine bridges
CA2142780C (en) Process for obtaining insulin having correctly linked cystine bridges
AU662083B2 (en) Process for obtaining proinsulin possessing correctly linked cystine bridges
HK1010457B (en) Process to obtain insulin with correct cystin bridges
HU215582B (hu) Eljárás humán inzulin N-terminális szekvenciájának enzimes eltávolítására
HUT63457A (en) Process for producing triarginine insulins
DK172242B1 (da) Fremgangsmåde til fremstilling af insulinderivater
US7659363B2 (en) Process for the preparation of insulin or an insulin derivative in the presence of oxygen
EP0570244B1 (en) Process for preparing peptides having a C-terminal proline amide
MXPA98006666A (en) Improved procedure for the obtaining of insulin precursors with cistina bridges correctly uni
HK1119449B (en) Process for obtaining insulin or insulin derivatives having correctly bonded cystine bridges
HK1061870B (en) Improved process for obtaining insulin precursors having correctly bonded cystine bridges
HK1003839B (en) Process for preparing peptides having a c-terminal proline amide

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: ON=AVENTIS PHARMA DEUTSCHLAND GMBH; FT=FORMER NAME

TC Change of applicant's name (sec. 104)

Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH

Free format text: FORMER NAME: HOECHST MARION ROUSSEL DEUTSCHLAND GMBH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired